BioNTech BNTX 深 滬
交易中 06-24 11:03:57 美东时间
90.36
-0.260
-0.29%
華盛通- 最 高91.11
- 今 開90.30
- 成交量 28.09万股
- 最 低 89.33
- 昨 收 90.62
- 總市值 228.51亿
- 52周最高 124.00
- 市盈率 靜 --
- 換手率 0.11%
- 52周最低 79.52
- 委 比 -69.76%
- 總股本 2.53亿
- 歷史最高 462.4502
- 量 比 1.71
- 振 幅 1.96%
- 歷史最低 10.9752
- 每 手 1
- 風險率 8.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Moderna snaps after six-session winning streak
Moderna (MRNA) snapped a six-session winning streak on Monday, with shares falling 6.10% to $60.06 in afternoon trading. Despite the decline, the stock has been one of the market's standout performers...
06-23 02:05
Moderna gains unanimous FDA panel endorsement of flu vaccine
A US FDA advisory panel unanimously agreed that the benefits of Moderna's (MRNA) mRNA seasonal flu vaccine, mRNA-1010, outweigh the risks in individuals 50-75 years old. The agency's Vaccines and Rela...
06-19 05:00
'BioNTech Investor Förtsch Says Founders' Spinout Raises Concerns' - Bloomberg News
https://www.bloomberg.com/news/articles/2026-06-17/biontech-investor-fortsch-says-founders-spinout-raises-concerns
06-18 00:18
Moderna eyes German production sites amid BioNTech plant closures - report
U.S. vaccine maker Moderna (MRNA) is exploring investments in manufacturing facilities in Germany and is particularly interested in acquiring sites that rival BioNTech (BNTX) plans to shut down as par...
06-17 15:19
科伦博泰与宜联生物的“同门战争”启示录
（本文作者为 医曜，钛媒体经授权发布） 文 | 医曜 上周五（6月12日）盘前，科伦博泰发布公告称，近日收到宜联生物就YL201项目对外授权应分享的6.0...
06-15 13:22
UPDATE 1-Commission appeal in COVID vaccine contract case should be dismissed, EU court adviser says
UPDATE 1-Commission appeal in COVID vaccine contract case should be dismissed, EU court adviser says Adds comments from Advocate General in paragraphs 2-3; details paragraphs 5-9 BRUSSELS, June 11 (Reuters) - An adviser to Europe's top court on Thursday recommended it to dismiss an appeal lodged by
06-11 17:35
FOCUS-Cancer vaccines based on mRNA advance, despite US cuts
FOCUS-Cancer vaccines based on mRNA advance, despite US cuts mRNA cancer vaccines show lasting benefit in melanoma, early promise in pancreatic and brain cancers US officials send mixed signals, with funding cuts despite ongoing NCI support Researchers highlight mRNA's potential, with new advances i
06-09 18:00
Arcus Biosciences Enters Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb; Will Supply Casdatifan, Its Investigational Small-Molecule HIF-2a Inhibitor
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
06-03 20:11
Full Transcript: Bristol-Myers Squibb Q1 2026 Earnings Call
On Thursday, Bristol-Myers Squibb (NYSE:BMY) discussed first-quarter financial ...
06-01 20:06
